Patents by Inventor Ingo Flamme

Ingo Flamme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-sema3a antibodies and uses thereof
    Patent number: 12173068
    Abstract: The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ?60%, ?70%, ?80%, or ?90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ?10 nM, ?5 nM, ?2.
    Type: Grant
    Filed: December 29, 2023
    Date of Patent: December 24, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Dorian Schönfeld, Karoline Dröbner, Ernst Weber, Katharina Filarsky, Philipp Ellinger, Fionnuala Mary McAleese Eser, Ingo Flamme, Winfried Wunderlich, Antje Schmidt, Yalda Sedaghat, Kenneth Young
  • MASP INHIBITORY COMPOUNDS AND USES THEREOF
    Publication number: 20240124522
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Application
    Filed: April 12, 2023
    Publication date: April 18, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald Bierer, Ingo Flamme, Dmitry Zubov, Thomas Neubauer, Adrian Tersteegen, Cathleen Juhl, Marie Glatz, Jan Dreher, Simon Holton, Carsten Terjung, Lars Baumann, Thorsten Poethko, Jiancheng Xiong, Yibo Qiu
  • MASP inhibitory compounds and uses thereof
    Patent number: 11667675
    Abstract: The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
    Type: Grant
    Filed: December 30, 2020
    Date of Patent: June 6, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Donald Bierer, Ingo Flamme, Dmitry Zubov, Thomas Neubauer, Adrian Tersteegen, Cathleen Juhl, Marie Glatz, Jan Dreher, Simon Holton, Carsten Terjung, Lars Baumann, Thorsten Poethko, Jiancheng Xiong, Yibo Qiu
  • Polyethylene glycol based prodrug of adrenomedullin and use thereof
    Patent number: 10035818
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 31, 2018
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
  • Polyethylene glycol based prodrug of adrenomedullin and use thereof
    Patent number: 9649363
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: May 16, 2017
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
  • Polyethylene glycol based prodrug of adrenomedullin and use thereof
    Patent number: 9603936
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: March 28, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
  • POLYETHYLENE GLYCOL BASED PRODRUG OF ADRENOMEDULLIN AND USE THEREOF
    Publication number: 20160367636
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Application
    Filed: December 31, 2015
    Publication date: December 22, 2016
    Inventors: Ingo Flamme, Johannes Kobberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Kollnberger, Frank Wunder, Gordon Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
  • Tyrosine based linkers for the releasable connection of peptides
    Patent number: 9315543
    Abstract: The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: April 19, 2016
    Assignees: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Ursula Krenz
  • Substituted dihydropyrazolones for treating cardiovascular and hematological diseases
    Patent number: 9168249
    Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: October 27, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Jörg Keldenich, Metin Akbaba, Mario Jeske
  • 4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases
    Patent number: 9085572
    Abstract: The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: July 21, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ingo Flamme, Jens-Kerim Ergüden, Felix Oehme, Kai Thede, Gunter Karig, Alexander Kuhl, Hanno Wild, Joachim Schuhmacher, Peter Kolkhof, Lars Bärfacker, Joachim Hütter
  • Substituted dihydropyrazolones for treating cardiovascular and hematological diseases
    Patent number: 8987261
    Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: February 18, 2013
    Date of Patent: March 24, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Jörg Keldenich, Metin Akbaba, Mario Jeske
  • TYROSINE BASED LINKERS FOR THE RELEASABLE CONNECTION OF PEPTIDES
    Publication number: 20150051160
    Abstract: The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.
    Type: Application
    Filed: October 29, 2012
    Publication date: February 19, 2015
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Lop, Sven Wittrock, Ursula Krenz
  • Substituted benzyl and phenylsulfonyl triazolones, and use thereof
    Patent number: 8859601
    Abstract: The present application relates to new, substituted benzyl-1,2,4-triazolones and phenylsulfonyl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.
    Type: Grant
    Filed: November 26, 2009
    Date of Patent: October 14, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulf Brüggemeier, Ingo Flamme, Chantal Fürstner, Joerg Keldenich, Peter Kolkhof, Martina Delbeck, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Truebel
  • POLYETHYLENE GLYCOL BASED PRODRUG OF ADRENOMEDULLIN AND USE THEREOF
    Publication number: 20140287984
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 25, 2014
    Applicants: Bayer Pharmaaktiengesellschaft, Bayer Intellectual Property GMBH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, July Marley, Iain Pritchard
  • Substituted dihydropyrazolones for treating cardiovascular and hematological diseases
    Patent number: 8653111
    Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: February 18, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Jörg Keldenich, Metin Akbaba, Mario Jeske
  • Substituted dipyridyl-dihydropyrazolones and use thereof
    Patent number: 8609698
    Abstract: The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: December 17, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Hanno Wild, Peter Kolkhof, Hartmut Beck, Mario Jeske
  • Substituted dihydropyrazolones and their use
    Patent number: 8580778
    Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: November 12, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Mario Jeske, Ingo Flamme, Friederike Stoll, Hartmut Beck, Metin Akbaba
  • Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors
    Patent number: 8524699
    Abstract: The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: September 3, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Kai Thede, Ingo Flamme, Felix Oehme, Jens-Kerim Ergüden, Friederike Stoll, Joachim Schuhmacher, Hanno Wild, Peter Kolkhof, Hartmut Beck, Metin Akbaba, Mario Jeske
  • Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof
    Patent number: 8404709
    Abstract: The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: March 26, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Santiago Figueroa Perez, Peter Kolkhof, Lars Bärfacker, Ingo Flamme, Karl-Heinz Schlemmer, Rolf Grosser, Klaus Münter, Andreas Knorr, Adam Nitsche
  • Aryl-or heteroaryl-substituted pyrido[2,3-d] pyrimidines and pharmaceutical compositions of the same
    Patent number: 8399471
    Abstract: The present application relates to novel aryl- or heteroaryl-substitued pyrido[2,3-d] pyrimidines of formula (I), pharmaceuitical compositions of the same, and a process for their preparation. Formula(I) is: wherein Ar is an aryl or heteroaryl substituent, and R1, R2, R3, Ar, D, and E are as defined in the specification. Compounds and compositions of the present invention can be used in the treatment and/or prophylaxis of various disorders in humans and animals, including aldosteronism, high blood pressure, chronic heart failure, the sequelae of a myocardial infarction, cirrhosis of the liver, renal failure, and stroke.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: March 19, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Santiago Figueroa Perez, Peter Kolkhof, Lars Bärfacker, Ingo Flamme, Karl-Heinz Schlemmer, Alexander Kuhl, Rolf Grosser, Klaus Münter, Andreas Knorr